IP Library Granted Patent US 8,445,527
Granted Patent B2
US 8,445,527 · App. 13/477,866 · Granted May 21, 2013

Organic compounds and their uses

Inventors: Michael Patane (Andover, MA); Prakash Raman (Acton, MA); David Thomas Parker (Lexington, MA); Jiping Fu (Arlington, MA); Branko Radetich (Boston, MA); Mohindra Seepersaud (Belmont, MA); Aregahegn Yifru (Somerville, MA); Rui Zheng (Arlington, MA); Trixi Brandl (Basel, CH); Francois Lenoir (Waltham, MA); Pascal Rigollier (Mulhouse, FR); Oliver Simic (Basel, CH)
Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,527
App. No.
13/477,866
Granted
May 21, 2013
Kind
B2
Abstract

The present invention provides a method of treating a HCV infection in a subject in need thereof by administering a compound of Formula I: or pharmaceutically acceptable salts thereof or stereoisomers thereof.

Claims (41)

1. A method of treating HCV infection in a subject in need thereof, comprising:

administering to the subject a pharmaceutically acceptable amount of a compound of the Formula I:

or a pharmaceutically acceptable salt or stereoisomer thereof;

wherein

y is 0 or 1;

n and p are each independently 0, 1 or 2;

R 14 is C(O) or SO 2 ;

R 1 , R 2 , W, R 13 and V are each, independently, selected from hydrogen or from the group consisting of alkyl, alkyl-aryl, heteroalkyl, heterocyclyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyloxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocyclyloxy, cycloalkyloxy, amino, alkylamino, arylamino, alkyl-arylamino, arylamino, heteroarylamino, cycloalkylamino, carboxyalkylamino, mono- and di-alkylcarboxamide, aralkyloxy and heterocyclylamino; each of which may be further independently substituted one or more times with X 1 and X 2 ; wherein X 1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, aralkyl, aryloxy, arylthio, arylheteroaryl, heteroaryl, heterocyclylamino, alkylheteroaryl, or heteroaralkyl; wherein X 1 can be independently substituted with one or more X 2 moieties which can be the same or different and are independently selected; wherein X 2 is hydroxy, oxo, alkyl, cycloalkyl, spirocycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, thio, alkylthio, amino, mono- and di-alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyl, alkoxycarbonyloxy, alkylureido, arylureido, halogen, cyano, or nitro; wherein each X 2 residue selected to be alkyl, alkoxy, and aryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different and are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, aralkyl, arylheteroaryl, heteroaryl, heterocyclylamino, alkylheteroaryl and heteroaralkyl;

W is also selected from the group consisting of C(O)—C(O)H, C(═N—O—R 24 )—C(O)-amine, C(O)—C(O)-amine, C(O)NR 24 S(O) p R 24 , C(O)NR 24 S(O) p N(R 24 ) 2 and C(O)-[C(O)] a -heterocycle, wherein the heterocycle may be independently substituted one or more times with aryl, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, and C 3-6 -cycloalkyl, wherein a is 0 or 1, wherein each R 24 is independently selected from hydrogen or the group consisting of C 1-4 -alkyl, C 3-6 -cycloalkylC 0-4 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle, each of which may be independently substituted one or more times with a halogen atom or C 1-4 -alkyl;

V is also selected from the group consisting of -Q 1 -Q 2 , wherein Q 1 is absent, C(O), N(H), N(C 1-4 -alkyl), C═N(CN), C═N(SO 2 CH 3 ), C═N—COH—C 1-4 -alkyl, or C═N—COH, and Q 2 is hydrogen or is selected from the group consisting of C 1-4 -alkyl, O—C 1-4 -alkyl, NH 2 , N(H)—C 1-4 -alkyl, N(C 1-4 -alkyl) 2 , SO 2 -aryl, SO 2 —C 1-4 -alkyl, C 3-6 -cycloalkyl-C 0-4 -alkyl, aryl, heteroaryl and heterocycle, each of which may be independently substituted one or more times with a halogen atom, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, or C 3-6 -cycloalkyl;

or R 1 and R 2 may together form a 3, 4, 5, 6 or 7-membered ring that is aromatic or non-aromatic and may contain one or more heteroatoms, wherein the ring may be further substituted one or more times;

R 3 is selected from the group consisting of hydrogen, C 1-4 -alkyl and C 3-6 cycloalkylC 0-4 alkyl;

the divalent residue:

is selected from the group consisting of:

R 8 , R 9 , R 10 , R 11 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-4 -alkyl and C 3-6 cycloalkylC 0-4 alkyl;

or R 3 and W may together form a 3, 4, 5, 6 or 7-membered ring that is aromatic or non-aromatic and may contain one or more heteroatoms, wherein the ring may be further substituted one or more times; and

or when y is 0, R 10 and V may together form a 3, 4, 5, 6 or 7-membered ring that is aromatic or non-aromatic and may contain one or more heteroatoms, wherein the ring may be further substituted one or more times.

2. The method of claim 1 , wherein

y is 0 or 1;

n is 0 or 1;

R 14 is C(O) or SO 2

R 1 is selected from the group consisting of H and C 1-4 -alkyl;

R 2 is selected from the group consisting of C 1-4 -alkyl, C(O)C 1-4 -alkyl, C(O)OC 1-4 -alkyl, and C 3-6 cycloalkylC 0-4 alkyl;

or R 1 and R 2 together form a cyclopropane ring;

W is selected from the group consisting of C(O)—C(O)H, C(═N—O—R 24 )—C(O)-amine, C(O)—C(O)-amine, C(O)NR 24 S(O) p R 24 , C(O)NR 24 S(O) p N(R 24 ) 2 and C(O)-[C(O)] a -heterocycle, wherein the heterocycle may be independently substituted one or more times with aryl, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, and C 3-6 -cycloalkyl, wherein a is 0 or 1, wherein each R 24 is independently selected from hydrogen or from the group consisting of C 1-4 -alkyl, C 3-6 cycloalkylC 0-4 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle, each of which may be independently substituted one or more times with a halogen atom or C 1-4 -alkyl;

p is 0, 1 or 2;

R 3 is selected from the group consisting of H and C 1-4 -alkyl;

R 13 is H;

R 9 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-4 -alkyl and C 3-6 -cycloalkyl; and

V is selected from the group consisting of -Q 1 -Q 2 , wherein Q 1 is absent, C(O), N(H), N(C 1-4 -alkyl), C═N(CN), C═N(SO 2 CH 3 ), C═N—COH—C 1-4 -alkyl, or C═N—COH, and Q 2 is hydrogen or is selected from the group consisting of C 1-4 -alkyl, O—C 1-4 -alkyl, NH 2 , N(H)—C 1-4 -alkyl, N(C 1-4 -alkyl) 2 , SO 2 -aryl, SO 2 —C 1-4 -alkyl, C 3-6 -cycloalkyl-C 0-4 -alkyl, aryl, heteroaryl and heterocycle, each of which may be independently substituted one or more times with a halogen atom, C 1-4 -alkyl, C 1-4 -alkyl substituted by one or more halogen atoms, or C 3-6 -cycloalkyl;

or R 3 and W can together form a 6-membered ring of the formula II:

wherein formula II may be further substituted;

or when y is 0, R 10 and V can form a cyclopropyl ring that may be further substituted by an amide group.

3. The method of claim 1 , wherein R 14 is C(O).

4. The method of claim 1 , wherein R 1 and R 2 , are independently selected from hydrogen or from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkylC 0-4 alkyl, C 3-6 cycloalkenylC 0-4 alkyl, C 1-4 alkoxyC 0-4 alkyl, and heterocycloalkylC 0-4 alkyl, each of which is unsubstituted or substituted with one or more groups selected from fluoro, chloro, hydroxy, C 1-2 alkylS, C 1-2 alkylS(O), and C 1-2 alkylS(O) 2 , and wherein the heterocycloalkyl is a 3 to 6 membered ring having one or two N, O or S ring atoms.

5. The method of claim 1 , wherein R 1 is hydrogen and R 2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, allyl, propargyl, 3-fluoro-n-propyl, n-butyl, n-pentyl, iso-propyl, sec-butyl, iso-butyl, 3-methyl-n-butyl, 3,3,3-trifluoro-n-propyl, 2,2-difluoroethyl, trifluoromethyl, 1,1-difluoro-n-propyl, 2,2,2-trifluoroethyl, 2,2-difluoro-n-but-3-enyl, 4-pentenyl, 3,3-difluoro-allyl, 2-methyl-allyl, 3-butenyl, 2-cyanoethyl, 3,3-difluoropropyl, 2,2-difluoro-3-butenyl, 2,2-difluoro-n-propyl, 4,4,4-trifluorobutyl, C 3-6 cycloalkyl, oxetan-2-ylmethyl, thietan-2-ylmethyl, 3-fluorocyclobutylmethyl, 3-hydroxycyclobutylmethyl, 3-butynyl, methoxymethyl, 2-methoxyethyl, methyl-S(O) 0-2 C 1-2 alkyl, 3,3-difluorocyclobutylmethyl, oxetan-3-ylmethyl, C 3-6 cycloalkylmethyl, 1-methylcyclopropylmethyl, C 3-6 cycloalkyl-difluoromethyl, C 3-6 cycloalkylethyl, thietan-3-ylmethyl, 1-fluorocyclobutylmethyl, 1-fluorocyclopropylmethyl, 2,2-difluorocyclopropylmethyl, and cyclopenten-2-ylmethyl.

6. The method of claim 1 , wherein W is selected from the group consisting of C(O)—C(O)NH 2 , C(O)—C(O)N(H)-cyclopropyl, C(O)-benzothiazole, C(O)-benzoimidazole, C(O)-oxazole, C(O)-imidazole, and C(O)-oxadiazole, wherein the benzothiazole, benzoimidazole, oxazole and oxadiazole groups may be independently substituted one or more times with a halogen atom, aryl, trihalomethyl, C 3-6 -cycloalkyl or C 1-4 -alkyl.

7. The method of claim 1 , wherein W is selected from the group consisting of

wherein R 19 is selected from the group consisting of hydrogen, aryl, trihalomethyl, and C 1-4 -alkyl.

8. The method of claim 1 , wherein R 11 is H and R 12 is C 3-6 -cycloalkyl.

9. The method of claim 1 , wherein W is selected from the group consisting of C(O)—C(O)N(R 23 ) 2 , wherein R 23 is independently selected from hydrogen or from the group consisting of C 1-4 -alkyl, C m -cycloalkylC 0-4 alkyl, aryl and heterocycle, each of which may be independently substituted one or more times with a halogen atom or C 1-4 -alkyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2012
From: PARKER, DAVID THOMAS; SEEPERSAUD, MOHINDRA; RADETICH, BRANKO; YIFRU, AREGAHEGN; RAMAN, PRAKESH; FU, JIPING; ZHENG, RUI; LENOIR, FRANCOIS; PATANE, MICHAEL; SIMIC, OLIVER; BRANDL, TRIXI; RIGOLLIER, PASCAL
To: NOVARTIS AG
Reel/Frame 028987/0226 →
Continuity (5)
Continuation 12879644 · Sep 10, 2010
Continuation 11697894 · Apr 9, 2007
Provisional Application 60866874 · Nov 22, 2006
Provisional Application 60791318 · Apr 11, 2006
Related Publication 20120231998A1 · Sep 13, 2012